MindMedMNMD
MNMD
About: Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Employees: 74
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
105% more call options, than puts
Call options by funds: $7.79M | Put options by funds: $3.8M
95% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 21
11% more funds holding
Funds holding: 171 [Q4 2024] → 189 (+18) [Q1 2025]
4% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 46
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
2.0% less ownership
Funds ownership: 56.6% [Q4 2024] → 54.59% (-2.0%) [Q1 2025]
17% less capital invested
Capital invested by funds: $289M [Q4 2024] → $240M (-$48.4M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$20
179%
upside
Avg. target
$20
179%
upside
High target
$20
179%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Rudy Li | 179%upside $20 | Buy Maintained | 9 May 2025 |
Financial journalist opinion
Based on 7 articles about MNMD published over the past 30 days
Neutral
Business Wire
5 days ago
MindMed Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 128,750 common shares of the Company (the "Options"), with effective grant dates of June 2, 2025 and June 9, 2025, depending on the appli.
Positive
The Motley Fool
1 week ago
Why Mind Medicine Gave Investors a Powerful Buzz in May
Mind Medicine (MNMD 2.81%), a healthcare company that's looking to develop treatments based on psychedelic compounds, was something of a sleeper stock in May. Several positive developments pushed the highly specialized enterprise's share price higher, to the point where it closed the month up almost 14% in price.
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade
The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 237.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
Business Wire
2 weeks ago
MindMed to Participate in June Investor Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Jefferies Global Healthcare Conference Format: Presentation Date and Time: Thursday, June 5, 2025 at 12:50 PM ET Location: New York, NY Webcast Link: Jefferies Glo.
Neutral
Business Wire
2 weeks ago
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed's executive leadership team where she will oversee all aspects of financial strategy, capital planning, accounting, in.
Positive
The Motley Fool
3 weeks ago
Why Mind Medicine Stock Vaulted More Than 8% Higher Today
Investors had a good mind to plow money into Mind Medicine (MNMD 8.13%) stock on Tuesday. Shares of the psychedelic-focused biotech, which also goes by the name of MindMed, provided a nice high by rising more than 8% in price on a legislative development.
Neutral
Business Wire
3 weeks ago
MindMed Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 53,350 common shares of the Company (the "Options"), with effective grant dates of May 5, 2025 and May 19, 2025, depending on the applic.
Positive
Zacks Investment Research
1 month ago
Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?
The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 279.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
Business Wire
1 month ago
MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will present at the 2025 RBC Capital Markets Global Healthcare Conference: 2025 RBC Capital Markets Global Healthcare Conference Format: Fireside Chat and 1x1 Meetings Date: May 21, 2025, at 2:05 PM ET Location: New Yor.
Neutral
Seeking Alpha
1 month ago
Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - Chief Executive Officer Matt Wiley - Chief Commercial Officer Dan Karlin - Chief Medical Officer Conference Call Participants Madhu Yennawar - Leerink Partners Brian Abrahams - RBC Capital Markets Elaine Kim - Cantor Rudy Li - Chardan Sumant Kulkarni - Canaccord Genuity Michael Okunewitch - Maxim Group Operator Good morning, and welcome to the MindMed's First Quarter 2025 Financial Results and Corporate Update Webcast. Currently, all participants are in listen-only mode.
Charts implemented using Lightweight Charts™